Silexion Closes $2.5M Public Offering with Warrants and Converts Sponsor Note

summarizeSummary

Silexion Therapeutics closed a $2.5 million public offering of shares and warrants, converted $750,001 of debt into equity, and now estimates shareholders' equity at $3.2 million.

check_boxKey Events · Financing and Capital Events · SLXN

• Public Offering Closed

  A public offering of 2,028,619 ordinary shares, 1,817,542 pre-funded warrants, and 3,846,161 Series E ordinary warrants at $0.65 per unit closed, raising approximately $2.5 million in gross proceeds.

• Sponsor Note Converted

  The company converted $750,001 of the Sponsor Note held by Moringa Sponsor, L.P. into 1,153,848 ordinary shares at $0.65 per share, reducing the note balance to $206,462.

• Pre-Funded Warrants Exercised

  Prior to closing, 823,770 pre-funded warrants were exercised, adding to the share count and further diluting existing shareholders.

• Estimated Shareholders' Equity

  After giving effect to the offering, note conversion, and warrant exercises, the company estimates shareholders' equity at approximately $3.2 million as of June 30, 2026, adjusted.

auto_awesomeAnalysis · SLXN · Life Sciences

On August 13, 2026, Silexion Therapeutics closed a $2.5 million public offering, issuing 2,028,619 ordinary shares, 1,817,542 pre-funded warrants, and 3,846,161 Series E ordinary warrants at $0.65 per unit. The offering was priced at a premium to the current stock price of $0.4599, but the warrants and pre-funded warrants create significant potential dilution. The company also converted $750,001 of its Sponsor Note into 1,153,848 ordinary shares at the same $0.65 price, reducing the note balance to $206,462. The net proceeds of approximately $2.1 million will fund the SIL204 clinical trial and general corporate purposes. This capital raise is critical for a company with a going concern warning and a market cap of only $489,033, but the dilutive structure and low share price reflect the company's distressed position.